Your search for ESKD returned 90 results

Hemoglobin levels lower, erythropoietin stimulating agent use higher, even for water lead levels below EPA threshold for regulatory action

For patients with type 2 diabetes, intensive glucose control has long-term benefits for preventing end-stage kidney disease (ESKD), according to a study published online March 22 in Diabetes Care.

Can gabapentin relieve two common symptoms associated with chronic kidney disease (CKD) and end-stage kidney disease (ESKD)?

Psoriasis may be another risk factor for infectious complications in patients receiving dialysis, according to investigators.

Although more research is needed, data suggest that the cardioprotective effect of direct oral anticoagulants may extend to patients with advanced CKD.

Patients with end-stage kidney disease (ESKD) undergoing maintenance dialysis express a desire to exercise to regain energy and strength, but many report barriers to exercise.

In patients with IgA nephropathy, dapagliflozin significantly reduced the risk of CKD progression when added to ACEi/ARB therapy.

A recent study examines the benefits and harms of vitamin B therapy in patients with diabetic kidney disease.

Investigators report results from a systematic review and meta-analysis of data from 23 randomized controlled trials involving 15,144 patients with anemia of CKD.

“We believe that the data actually suggest possible benefit for ESKD [end-stage kidney disease] with intensive glucose control, and remain inconclusive for intensive blood pressure control and fibrate use given the wide confidence intervals for the more reliable ESKD outcomes,” write the authors.